Latest news for Aerkomm (OTC:AKOM) Stock

Aerkomm Inc is an a development stage satellite communication technology company providing carrier-neutral and software-defined infrastructure to deliver mission-critical, multi-orbit satellite broadband connectivity for the public and private sectors. It offer a range of next-generation technologies that bring high-throughput performance, interoperability and virtualization to provide high performance and resilient end-to-end broadband connectivity to our customers in collaboration with satellite or constellation partners and mobile network operators.

Aerkomm Inc

WIIM

CVGW

Calavo Growers shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

PRTH

Priority Technology shares are trading lower after the company announced a share offering of 9,157,600 shares.

CEO Marc Rowan to Enter Into 5-Year Employment Agreement Extension
Jim Zelter Named President of Apollo Global Management
John Zito Named Co-President of Apollo Asset Management Alongside Scott Kleinman
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) today announced that Jim Zelter has been named President of Apollo Global Management, Inc. (AGM), the holding company for its asset management and retirement services businesses. The newly created role reflects Apollo's continued operational expansion and its significant growth plans across both the Apollo Asset Management, Inc. (AAM) and Athene Holding Ltd. subsidiaries. As President, Zelter will work closely with AGM CEO Marc Rowan to drive Apollo's recently announced five-year plan and lead a number of key strategic initiatives across its asset management and retirement services businesses.

News

Management

Apollo Announces Jim Zelter As President Of Apollo Global Management; John Zito Named Co-President Of Apollo Asset Management With Scott Kleinman; CEO Marc Rowan Signs 5-Year Agreement Extension

TOMZ

TOMI Environmental Solutions Regains Compliance With Nasdaq Requirements

GNLN

Greenlane Regains Full Compliance With Nasdaq Continued Listing Rules
ACCESSWIRE

KROS

Keros Therapeutics shares are trading lower after the company announced an update on its Phase 2 TROPOS trial and halted all dosing based on the ongoing safety review.

JP Morgan analyst Tami Zakaria maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $450 to $470.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on Deere, Raises Price Target to $470

QUBT

Quantum Computing Collaborates With Sanders Tri-Institutional Therapeutics Discovery Institute To Support Research Using Dirac-3 Systems

BECN

QXO Proposes To Acquire Beacon Roofing Supply For $124.25/Share In Cash, Implying Total Transaction Valued Of ~$11B

Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company's FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.
xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. xT CDx leverages a normal-matched approach, which is a method of parallel DNA sequencing of a solid tumor and normal patient sample that can lead to more accurate identification of cancer-driving somatic variants. All orders for tumor + normal match tests – traditionally run on the company's signature xT assay – will now be run as xT CDx with no changes to the current ordering workflow.

Biotech

General

Tempus Announces The Launch Of FDA-Approved xT CDx Test, Now Available For All Ordering Clinicians Nationwide

Guidance

MYGN

Myriad Genetics Sees FY25 Adj. EPS $0.07-$0.11 Vs $0.08 Est.; Revenue $840M-$860M Vs $876.702M Est.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>)&nbsp;a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.
H5N1 is a viral infection often contracted by contact with sick birds, yet it can also be passed from person to person. Symptoms begin within two to eight days and can seem like the common flu, causing cough, fever, sore throat, muscle aches, headache, and shortness of breath. The disease can carry a high mortality in humans. Some antiviral drugs, if taken within two days of symptoms, may help. Last week, the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4340843-1&amp;h=149896997&amp;u=https%3A%2F%2Fldh.la.gov%2Fnews%2FH5N1-death&amp;a=Louisiana+Department+of+Health+recently+reported+the+first+U.S.+death+from+H5N1">Louisiana Department of Health recently reported the first U.S. death from H5N1</a>.

TCBP

TCBP Announces That It Intends To Begin Proof Of Concept Preclinical Studies For Its Lead Therapeutic TCB008, For Treatment In H5N1, Commonly Known As "Bird Flu"

Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.03-$0.04 Vs $0.03 Est.; Revenue $209M-$211M Vs $212.873M Est.

JP Morgan analyst Tami Zakaria maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Neutral and raises the price target from $12 to $13.

JP Morgan Maintains Neutral on CNH Industrial, Raises Price Target to $13

UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) is gearing up to release its<a href="https://www.benzinga.com/quote/UNH/earnings"> fourth quarter earnings report</a>, and investors are watching closely. Stephanie Link, CIO at Hightower Advisors LLC, has dubbed the managed care giant the &#8220;number one company on sale&#8221; despite potential near-term earnings pressure.
<h2 class="wp-block-heading">&#8216;They&#8217;re Probably Gonna Miss&#8217; Q4 Earnings Expectations </h2>
With estimated earnings per share (EPS) of $6.73 and revenue projections around $101.75 billion according to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Benzinga Pro</a> data, UnitedHealth faces scrutiny over high utilization rates that could dent its profit margins. 
On earnings, &#8220;they're probably gonna miss&#8230;because utilization rates are so strong, so high, and it hurts their cost,&#8221; Link <a href="https://www.cnbc.com/video/2025/01/14/trade-tracker-stephanie-link-buys-unitedhealth.html">remarked</a> during CNBC's Halftime Report. 
However, she sees this as a temporary hiccup, not a long-term trend.
Read Also: <a href="https://www.benzinga.com/general/health-care/24/12/42744629/unitedhealth-group-ceo-reportedly-says-company-will-hit-financial-records-execs-murder-public-outcry-are-backdrop-for-q4-earnings">UnitedHealth Group CEO Reportedly Says Company Will Hit Financial Records: Exec&#8217;s Murder, Public Outcry Are Backdrop For Q4 Earnings</a>
<h2 class="wp-block-heading">From Beat-And-Raise To Strategic Patience</h2>
UnitedHealth, long celebrated for its consistent earnings beats, hasn't seen much stock movement in the past year, but that hasn&#8217;t dampened Link&#8217;s enthusiasm. &#8220;They have a gem with Optum,&#8221; she said, referring to the segment responsible for 24% of the company's revenue and 12% of operating profits. 
Ongoing M&amp;A activity is bolstering Optum's growth trajectory, even as the broader healthcare sector struggles to find favor with investors.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png" alt="" class="wp-image-734548" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/15073053/Screenshot-2025-01-15-at-6.00.36-PM-300x233.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011525&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
Technically, UnitedHealth shares are experiencing bullish buying pressure, with the stock trading above its eight, 20 and 200-day simple moving averages (SMAs).
At $543.74 per share, the price positions UNH stock as a bullish signal across these metrics, although its moving average convergence/divergence (MACD) indicator of a negative 6.15 suggests caution. Meanwhile, UNH stock&#8217;s relative strength index (RSI) of 56.86 signals moderate strength but room for additional upward movement.
<h2 class="wp-block-heading">A Buying Opportunity In The Making?</h2>
Historically trading at a premium valuation, UnitedHealth now sits at 17 times earnings, compared to its typical 21 times multiple. &#8220;When I owned it, it was trading at something like 25 times, and every quarter was a beat and raise,&#8221; Link noted. Despite the temporary pressure, she believes the stock&#8217;s visibility will only improve post-earnings.
Link remains bullish on UnitedHealth&#8217;s potential, citing strong fundamentals, a promising $18 billion buyback program and expectations of double-digit earnings and revenue growth ahead. &#8220;We&#8217;re gonna see double-digit growth in earnings and revenues,&#8221; she emphasized, viewing current regulatory and litigation concerns as mere &#8220;noise.&#8221;
UnitedHealth's premium status as the &#8220;number one managed care company&#8221; may make today&#8217;s market lull a golden opportunity for savvy investors.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/insights/news/25/01/42776487/heres-how-much-you-would-have-made-owning-unitedhealth-group-stock-in-the-last-10-years">Here&#8217;s How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years</a></li>
</ul>
Photo: Shutterstock

Health Care

Technicals

Previews

Trading Ideas

UnitedHealth: The 'Number One Company On Sale' Ahead Of Q4 Earnings Report

Benchmark analyst Christopher Kuhn reiterates RXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) from Hold to Hold.

Reiteration

Benchmark Reiterates Hold on RXOto Hold

Expansion into South Africa &amp; Nigeria Marks Ispire's First International Nicotine License Arrangement &amp; Product Launch
LOS ANGELES, Jan. 15, 2025 /PRNewswire/ -- <a href="https://ispiretechnology.com/">Ispire Technology Inc.</a>&nbsp;("Ispire" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>), an innovator in vaping technology and precision dosing, announced the successful launch of its BrkFst nicotine products across South Africa and Nigeria, marking the Company's first international nicotine license arrangement and product launch. BrkFst, the brand co-created by GRAMMY-Award winner Burna Boy, is set to redefine the nicotine product market in these regions.

Global

ISPR

Ispire Technology Announces License Arrangement And Successful Launch Of Burna Boy's BrkFst Nicotine Products Into African Markets

Offerings

AZTR

Azitra Prices 4,857,780 Share Public Offering Of Common Stock At $0.30/Share

NANO Nuclear Energy Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) ("NANO Nuclear" or "the Company"), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced the rebranding of its recently acquired, patented Pylon Transportable Reactor Platform, which will now be known as LOKI MMR&#x2122;.
The LOKI MMR&#x2122; is a portable nuclear reactor designed for versatility in application and deployment. Designed to provide between 1.5MWe and 5MWe of power, it is tailored to specific applications ranging from remote terrestrial, marine, and space deployments. Its transportability via road, rail, sea, and air ensures adaptability for diverse deployment scenarios and supports scalability through interconnected systems to meet greater energy demands. While NANO Nuclear will explore different applications for LOKI MMR&#x2122;, it is anticipated that the LOKI MMR&#x2122; will particularly compliment NANO Nuclear's previously announced efforts to apply nuclear energy in space exploration.

NANO Nuclear Energy Announces LOKI MMR As The New Tradename For Its Newly Acquired Patented Pylon Transportable Reactor Platform

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has announced its inaugural Quantum Day, set to take place on Mar. 20 during the GTC 2025 event. The announcement comes just days after CEO Jensen Huang stated that practical quantum computing may <a href="https://www.benzinga.com/markets/equities/25/01/42867168/nvidias-jensen-huang-said-something-that-has-all-quantum-computing-stocks-tumbling-qubt-and-rgti-down-13-ionq-down-11">still be two decades away.</a>
What Happened: The event is set to spotlight the swift advancements in quantum computing, a technology expected to transform sectors like drug discovery, materials science, and financial forecasting. Huang will spearhead discussions with leaders from key industry players, including&nbsp;Alice &amp; Bob,&nbsp;Atom Computing, IONQ Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) and&nbsp;D-Wave (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>), the company said in a&nbsp;blog post on Wednesday.
Quantum Day will offer sessions exploring both the current and future potentials of quantum technology. These sessions will be led by Huang and other experts from the quantum field. Additionally, a developer day session will emphasize collaborations between NVIDIA and its partners to advance quantum computing technologies.
Why It Matters: Last week, during Nvidia's Analyst Day, CEO Huang shared his optimism about the future of quantum computing but cautioned that practical applications could still be 15 to 30 years away. 
"If you kind of said 15 years for very useful quantum computers, that would probably be on the early side. If you said 30, it's probably on the late side," he said.
Huang&#8217;s comments were backed by Meta Platforms Inc. CEO Mark Zuckerberg. <a href="https://www.benzinga.com/markets/equities/25/01/42936751/mark-zuckerberg-backs-nvidia-ceo-jensen-huangs-view-on-quantum-computing-its-still-quite-a-ways-off">During his appearance</a> on Joe Rogan's podcast Saturday, Zuckerberg admitted his limited expertise on the subject but aligned with the industry consensus, suggesting a decade-long timeline for the widespread adoption of quantum computing.
Meanwhile, despite Huang&nbsp;stating that practical quantum computing might be two decades away, NVIDIA is investing heavily in its future. The company is <a href="https://www.benzinga.com/markets/equities/25/01/42966492/jensen-huang-said-quantum-computing-is-20-years-away-but-nvidia-bets-big-on-strategic-hiring">strategically hiring to strengthen</a> its quantum computing capabilities. This indicates NVIDIA&#8217;s long-term commitment to integrating quantum and classical computing systems.
Moreover, the announcement comes at a time when quantum computing stocks are gaining momentum during Wednesday premarket. Following&nbsp;Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) declaration of making its business clients <a href="https://www.benzinga.com/markets/equities/25/01/42998134/qubt-qbts-up-12-rgti-gains-3-in-wednesday-premarket-quantum-computing-stocks-gain-momentum-after-microsoft-says-we-are-right-on-the-cusp-of-seeing-quantum-computers-solve-meaningful-problems">&#8220;quantum-ready&#8221; by 2025</a>, stocks like&nbsp;Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) and&nbsp;D-Wave Quantum&nbsp;have seen significant gains. This surge underscores the growing anticipation and investment in quantum computing technologies.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/42993297/bitcoin-ethereum-and-dogecoin-rebound-sharply-on-lighter-inflation-data-top-trader-says-despite-expectations-for-bull-market-to-be-over-its-an-ideal-climate-for-altcoins">Bitcoin, Ethereum, And Dogecoin Rebound Sharply On Lighter Inflation Data: Top Trader Says Despite Expectations For Bull Market To Be Over, It&#8217;s An Ideal Climate For Altcoins.</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

IONQ

MSFT

NVDA

QBTS

NVIDIA Announces First-Ever Quantum Day At GTC 2025, Days After Jensen Huang Said Quantum Computing Is 20 Years Away

AERKOMM to merge with blank-check firm IX Acquisition Corp

AKOM

IXAQ

Small Cap

Press Releases

AERKOMM Powers Ahead the Merger Plan with EJECTT Endeavoring in Global Military Communication Systems and 6G Opportunities

AERKOMM and Nasdaq-Listed IX Acquisition Corp. Announce Merger Agreement and US $35 Million Private Placement

AERKOMM Expands Presence in Asia Through New Partnership with Eutelsat's OneWeb LEO Services

IXAQU

Aerkomm

Comments

Aerkomm

News

Latest news for Aerkomm (OTC:AKOM) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga